Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy

Clinica Chimica Acta

Volumn 415, Issue , 2013, Pages 63-68

  Bosselut, Nelly ^a,b,c   Taibi, Ludmia ^a   Guéchot, JérÔme ^a   Zarski, Jean Pierre ^d,e   Sturm, Nathalie ^d,e   Gelineau, Marie Christine ^f   Poggi, Bernard ^d   Thoret, Sophie ^d   Lasnier, Elisabeth ^a   Baudin, Bruno ^a   Housset, Chantal ^b,c   Vaubourdolle, Michel ^a  

^a UNIVERSITÉ PARIS EST   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e INSTITUT ALBERT BONNIOT   (France)

^f CROIX ROUSSE HOSPITAL   (France)

Author keywords

Chronic hepatitis C; Collagen IV; Fibrosis score; Liver fibrosis; Osteoprotegerin

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; COLLAGEN TYPE 4; OSTEOPROTEGERIN;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; ALPHA-MACROGLOBULINS; APOLIPOPROTEIN A-I; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; COLLAGEN TYPE IV; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

HEPATITIS C VIRUS;

EID: 84867812807     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.09.020     Document Type: Article

References (29)

1. Cadranel J.F., Rufat P., Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the study of the Liver (AFEF). Hepatology 2000, 32:477-481.
2. Regev A., Berho M., Jeffers L.J., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
3. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
4. Sandrin L., Fourquet B., Hasquenoph J.M., et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003, 29:1705-1713.
5. Ziol M., Handra-Luca A., Kettaneh A., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41:48-54.
6. Castera L., Foucher J., Bernard P.H., et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010, 51:828-835.
7. Zarski J.P., Sturm N., Guechot J., et al. Comparison of 9 blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012, 56:55-62.
8. Cales P., Oberti F., Michalak S., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42:1373-1381.
9. Adams L., Bulsara M., Rossi E., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005, 51:1867-1873.
10. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075.
11. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
12. Tsuda E., Goto M., Mochizuki S., et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997, 234:137-142.
13. Moschen A.R., Kaser A., Stadlmann S., et al. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 2005, 43:973-983.
14. Garcia-Valdecasas-Campelo E., Gonzalez-Reimers E., Santolaria-Fernandez F., et al. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol 2006, 41:261-266.
15. Guanabens N., Enjuanes A., Alvarez L., et al. High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. J Bone Miner Metab 2009, 27:347-354.
16. Fabrega E., Orive A., Garcia-Suarez C., Garcia-Unzueta M., Antonio Amado J., Pons-Romero F. Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Liver Int 2005, 25:305-310.
17. Bosselut N., Barbu V., Henegar C., et al. Pangenomic profiling indicates distinct functions of portal and hepatic stellate cells-derived rat liver myofibroblasts in wound healing [Abstract]. J Hepatol 2010, 52(Supplement 1):S357.
18. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
19. Obuchowski N.A. An ROC-type measure of diagnostic accuracy when the gold standard is continuous-scale. Stat Med 2006, 25:481-493.
20. Lambert J., Halfon P., Penaranda G., Bedossa P., Cacoub P., Carrat F. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 2008, 54:1372-1378.
21. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
22. Votovski S., Phillips J.S., Sayers J., Croucher P.I. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 2007, 282:31601-31609.
23. Murawaki Y., Koda M., Okamoto K., Mimura K., Kawasaki H. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001, 16:777-781.
24. Castéra L., Foucher J., Bernard P.H., et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010, 51:828-835.
25. Myers R.P., Pomier-Layrargues G., Kirsch R., et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol 2012, 56:564-570.
26. Boursier J., de Ledinghen V., Zarski J.P., et al. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011, 106:1255-1263.
27. Mountzios G., Dimopoulos M.A., Bamias A., et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 2007, 46:221-229.
28. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
29. Vik A., Brodin E., Sveinbjornsson B., Hansen J.B. Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost 2007, 98:148-154.